FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection
BEIJING,Nov. 18,2024-- Huahui Health,a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis,hepatology,and oncology,today announce
MLBNov 19, 2024